Pyxis Diagnostics

Company Overview

Snapshot

Founded in April 2019 by Ravit Geva, Ilan Volovitz, Reut Yosef, and Aviv De Morgan, Pyxis Diagnostics operates with 1–10 employees. The company has secured funding across one round from three investors, including Israel Innovation Authority and Vincent Tchenguiz. In November 2025, Pyxis Diagnostics ceased operations.

Business overview

Pyxis Diagnostics is developing an AI-powered cancer diagnostics platform designed to predict the response to immuno-oncology (IO) drugs across various cancer types. The platform utilizes biological data from fresh tumor samples, including cell sorting, next-generation genetic sequencing, and proteomics, to deeply characterize cancer cells, immune cells, and stromal cells. This analysis delineates the cellular suppressive network within the tumor microenvironment, enabling machine-learning algorithms to classify responders and suggest alternative treatments, thereby improving patient outcomes and immunotherapy success rates in both clinical and drug development settings. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Medical Diagnostics.

Company Intelligence Q&A

What is Pyxis Diagnostics' core technology?

Pyxis Diagnostics develops an AI-powered cancer diagnostics platform that predicts immuno-oncology drug response. It uses machine learning algorithms to analyze biological data from tumor samples, characterizing cancer cells, immune cells, and stromal cells to delineate the cellular suppressive network within the tumor microenvironment.

When was Pyxis Diagnostics founded and by whom?

Pyxis Diagnostics was founded in April 2019 by Ravit Geva, Ilan Volovitz, Reut Yosef, and Aviv De Morgan.

What is the primary focus of Pyxis Diagnostics' platform?

The primary focus of Pyxis Diagnostics' platform is to predict immuno-oncology drug response for various cancer types and to suggest alternative treatment routes when predicted drug response is low, aiming to improve the quality of life for oncological patients.

What is the current operational status of Pyxis Diagnostics?

Pyxis Diagnostics ceased to operate in November 2025.

Which investors participated in Pyxis Diagnostics' funding round?

In September 2019, Pyxis Diagnostics received funding from Israel Innovation Authority and Vincent Tchenguiz.